Q-omics provides the consensus-scored NANOGP10 profile across patient tissues and cancer cell-line models. NANOGP10 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in GBM. Among the 18 cancer types available for tumor–normal comparison, NANOGP10 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, NANOGP10 RNA expression shows 6,036 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight GBM, LUAD, and STAD as cancer lineages where NANOGP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NANOGP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NANOGP10 survival associations across molecular data types. NANOGP10 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NANOGP10 RNA expression–survival associations across cancer types. High NANOGP10 expression shows unfavorable associations in GBM, COAD, LUAD and SKCM, but favorable associations in OV and MESO. The GBM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify GBM as the clearest survival context for NANOGP10 RNA expression.
This table summarizes NANOGP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for NANOGP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NANOGP10 shows higher tumor expression in LUAD. The LUAD box plot shows higher NANOGP10 RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p = .036).
This table shows molecular features associated with NANOGP10 in patient tissues and cancer cell lines. In patient samples, NANOGP10 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
